8 results about "Alveolar epithelial cell" patented technology

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

This invention discloses the application of NLRX1 protein inhibitors in the preparation of products with protective effects against pulmonary fibrosis, belonging to the field of biomedical technology. This invention, through the use of an NLRX1 gene knockout mouse model and siRNA silencing technology, demonstrates that inhibiting NLRX1 can significantly alleviate bleomycin-induced pulmonary fibrosis pathological damage. Its protective mechanisms include promoting the proliferation of type II alveolar epithelial cells, inhibiting their damage and apoptosis, and reducing myofibroblast infiltration and extracellular matrix deposition. Based on this, this invention provides for the first time a therapeutic strategy targeting the inhibition of the NLRX1 protein. Related products include recombinant vectors containing RNA molecules encoding NLRX1 expression inhibitors or other drugs capable of inhibiting NLRX1 expression. This invention provides new targets and drug development directions for the treatment of fibrotic diseases, especially pulmonary fibrosis.

This invention belongs to the field of targeted drug technology, and specifically relates to the application of PRDX3 protein as a drug target in screening drugs for the prevention and / or treatment of COPD induced by cigarette smoke. This invention demonstrates that the expression level of PRDX3 protein is increased in COPD mouse models and in cigarette smoke-induced MLE-12 alveolar epithelial cells, and also explores the effect of PRDX3 on COPD disease progression. Overexpression of PRDX3 in alveolar epithelial cells significantly improves lung function and lung tissue damage in COPD mice, while knockdown of PRDX3 exacerbates COPD symptoms in COPD mice. This invention provides a novel drug target and candidate compound for the treatment of COPD, and has significant clinical application value.

This invention provides a biomimetic microfluidic device for simulating the three-dimensional structure of alveoli. The fabrication method includes: preparing an inverse opal membrane; bonding the inverse opal membrane to the bottom of a transwell chamber structure (with the bottom filter membrane removed); bonding the top of the transwell chamber to a perforated plate cover; inserting one end of a gas delivery tube through the perforation in the perforated plate cover into the transwell chamber; and connecting the other end to an injection pump; culturing alveolar epithelial cells and vascular endothelial cells on the front and back sides of the inverse opal membrane, respectively, to obtain the biomimetic microfluidic device. The biomimetic microfluidic device provided by this invention can achieve three-dimensional stretching under the action of a microfluidic injection pump, simulating the periodic stretch-recovery process of human lung respiratory movement in vitro. The fabrication method is simple and reliable.

The application provides a method for regulating mechanical stretching force on SARS-CoV-2 pseudovirus invasion of alveolar epithelial cells. It comprises the following steps: screening SARS-CoV-2 pseudovirus infection titer capable of meeting infection efficiency; taking SARS-CoV-2 pseudovirus of the titer screened in step S1 to infect alveolar epithelial cells (ATII cells) in a biomimetic microfluidic alveolar cell chip, at the same time, applying gradient cyclic mechanical stretching force to the biomimetic microfluidic alveolar cell chip, monitoring the infection efficiency of SARS-CoV-2 pseudovirus by immunofluorescence staining, and establishing a relationship model between mechanical stretching force and infection efficiency; based on the relationship model between mechanical stretching force and infection efficiency, adjusting the mechanical stretching force, thereby adjusting the infection efficiency of SARS-CoV-2 pseudovirus in the biomimetic microfluidic alveolar cell chip. The application reveals that the stretching force can reduce the membrane tension of ATII cells, and further inhibit the infection efficiency of SARS-CoV-2 pseudovirus on ATII cells, thereby providing an important theoretical basis for elucidating the mechanical regulation mechanism of respiratory virus invasion.

This invention proposes a method for isocarbonyl hyperventilation to protect alveolar epithelial cells from oxidative damage. It belongs to the field of medical respiratory therapy technology. The method includes: providing patients requiring respiratory support with a minute ventilation volume higher than physiologically required, while simultaneously supplementing the inhaled air with exogenous carbon dioxide using a gas mixing device; continuously monitoring the patient's end-tidal carbon dioxide partial pressure, the concentration of 8-isoprostaglandin in exhaled condensate, and pH value, among other oxidative stress biomarkers, using monitoring equipment; and precisely regulating gas composition and ventilation parameters through isocarbonyl hyperventilation to create a suitable microenvironment for alveolar epithelial cells, effectively neutralizing excessive intracellular oxidative substances, reducing direct damage to cells from oxidative stress, and decreasing adverse effects such as cell membrane lipid peroxidation and protein denaturation, thereby significantly improving the survival rate and normal function maintenance capacity of alveolar epithelial cells.

The application relates to the field of biological medicine, and particularly relates to application of palmitic acid and a preparation thereof in preparation of a medicine for preventing and treating acute exacerbation of chronic obstructive pulmonary disease. The application provides application of palmitic acid and the preparation thereof in preparation of the medicine for preventing and treating acute exacerbation of chronic obstructive pulmonary disease. It is found by the application that supplement of palmitic acid in an acute infection period can improve IFITM3 protein expression of alveolar epithelial cells, and further promotes downstream secreted TGFbeta by up-regulating the expression level of an anti-inflammatory cytokine, so that lung tissue inflammation subsides and tissue repair is promoted, and lung function of a patient with chronic obstructive pulmonary disease is improved.